Durvalumab/Gefitinib |
|
Phase 2 Clinical |
Medimmune |
Carcinoma, Non-Small-Cell Lung |
Details
|
IMC-001 |
IMC-001; STI-3031; STI-A1015 |
Phase 2 Clinical |
Sorrento Therapeutics |
Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Neoplasm Metastasis; Gastrointestinal Neoplasms |
Details
|
GNC-038 |
GNC-038 |
Phase 1 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) |
|
Phase 1 Clinical |
Tianjin Mycure Medical Technology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CX-072 |
CX-072 |
Phase 2 Clinical |
Cytomx Therapeutics |
Triple Negative Breast Neoplasms; Breast Neoplasms; Lymphoma; Melanoma |
Details
|
Human source and Fc engineered monoclonal antibody (MabSpace) |
MSB-2311 |
Phase 1 Clinical |
Mabspace Biosciences |
Neoplasms |
Details
|
LY-3415244 |
LY-3415244 |
Phase 1 Clinical |
Eli Lilly And Company |
Neoplasms |
Details
|
FS 118 |
FS-118 |
Phase 1 Clinical |
Merck Serono, F-Star |
Hematologic Neoplasms; Neoplasm Metastasis |
Details
|
BMS-986189 |
BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Sepsis |
Details
|
Cosibelimab |
CK-301; TG-1501 |
Phase 1 Clinical |
Tg Therapeutics |
Lymphoma |
Details
|
FAZ-053 |
LAE-005; FAZ-053 |
Phase 1 Clinical |
Novartis Pharma Ag |
Triple Negative Breast Neoplasms; Chordoma |
Details
|
KD-045 (Nanjing KAEDI Biotech) |
KD-045 |
Phase 1 Clinical |
Nanjing Kaedi Biotechnology Co Ltd |
Neoplasms |
Details
|
KL-A167 |
A-167; KL-A167; HBM-9167 |
Phase 2 Clinical |
Sichuan Kelun Botai Biomedicine Co Ltd |
Lymphoma, B-Cell; Hodgkin Disease; Nasopharyngeal Carcinoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma |
Details
|
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) |
|
Phase 2 Clinical |
Changhai Hospital Of Shanghai |
Pancreatic Neoplasms |
Details
|
BGB-A333 |
BGB-A333 |
Phase 2 Clinical |
Beigene Ltd |
Neoplasms |
Details
|
艾姆地芬 |
|
Phase 1 Clinical |
Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences |
Solid tumours |
Details
|
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) |
Z-CTLs |
Phase 1 Clinical |
Hunan Zhaotai Yongren Biotech |
Carcinoma, Non-Small-Cell Lung |
Details
|
ALPN-202 |
ALPN-202 |
Phase 1 Clinical |
Alpine Immune Sciences |
Lymphoma |
Details
|
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) |
|
Phase 1 Clinical |
Jiangsu Huaiyu Pharmaceutical Co Ltd |
Neoplasms |
Details
|
JS-003 |
JS-003 |
|
Shanghai Junshi Biosciences Co Ltd |
Solid tumours |
Details
|
GS-4224 |
GS-4224 |
Phase 2 Clinical |
Gilead Sciences Inc |
Neoplasms; Hepatitis B |
Details
|
INBRX-105 |
INBRX-105 |
Phase 1 Clinical |
Inhibrx |
Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Esophageal adenocarcinoma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Anti PD-L1 monoclonal antibody (Biocad) |
BCD-135 |
Phase 1 Clinical |
Biocad |
Neoplasms |
Details
|
ES101 |
ES101 |
Phase 1 Clinical |
Inhibrx |
Neoplasms |
Details
|
IBI-322 |
IBI-322 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Hematologic Neoplasms; Neoplasms |
Details
|
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) |
|
Phase 1 Clinical |
The Second Hospital Of Nanjing Medical University |
Carcinoma, Hepatocellular |
Details
|
HLX-20 |
HLX-20 |
Phase 1 Clinical |
Shanghai Henlius Biotech Co Ltd |
Neoplasms |
Details
|
FPT-155 |
CD80-Fc; FPT-155 |
Phase 1 Clinical |
Five Prime Therapeutics |
Neoplasms |
Details
|
BMS-936559 |
MDX-1105; BMS-936559 |
Phase 3 Clinical |
Bristol-Myers Squibb Company |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Shock, Septic; Hodgkin Disease; Sepsis; Multiple Myeloma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
RG-6084 |
RG-6084 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Hepatitis B |
Details
|
MCLA-145 |
MCLA-145 |
Phase 1 Clinical |
Incyte Corp, Merus |
Neoplasms |
Details
|
IBI318 |
IBI-318; LY-3434172; LY3434172 |
Phase 2 Clinical |
Eli Lilly And Company, Innovent Biologics(Suzhou) Co Ltd |
Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular |
Details
|
IGV-001 |
IGV-001 |
Phase 2 Clinical |
Thomas Jefferson University |
Glioblastoma |
Details
|
IBI-323 |
IBI323; IBI-323 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours |
Details
|
18F-BMS-986192 |
BMS-986192-[18F] |
Clinical |
Bristol-Myers Squibb Company |
Neoplasms |
Details
|
89Zr-durvalumab |
|
Phase 2 Clinical |
Radboud University Nijmegen |
Head and Neck Neoplasms |
Details
|
Pd-1-pik |
Pd-1-pik |
Phase 1 Clinical |
Department Of Integrative Medicine, Huashan Hospital Of Fudan University, Shanghai, China |
Glioblastoma |
Details
|
LOR-S03 |
CDX-527; LOR-A04; LOR-S01; LOR-S03 |
Phase 1 Clinical |
Celldex |
Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Durvalumab/Selumetinib sulfate |
|
Phase 1 Clinical |
Astrazeneca Plc |
Neoplasms |
Details
|
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Peritoneal Neoplasms |
Details
|
CA-170 |
CA-170; AUPM-170 |
Phase 2 Clinical |
Aurigene |
Solid tumours; Neoplasms |
Details
|
GEN-1046 |
GEN1046; PD-L1x4-1BB; DuoBody-PD-L1x4-1BB |
Phase 2 Clinical |
Biontech Se, Genmab |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
CK-301 |
CK-301 |
Phase 1 Clinical |
Dana-Farber Cancer Institute |
Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Mesothelioma; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
ADG-104 |
ADG-104; ADG104 |
Phase 2 Clinical |
|
Neoplasms |
Details
|
ND-021 |
ND-021; NM21-1480 |
Phase 2 Clinical |
Numab Therapeutics Ag |
Solid tumours; Neoplasms |
Details
|
Recombinant human anti-PD-L1 monoclonal antibody (Guilin Sanjin) |
|
Phase 2 Clinical |
Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd |
Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Penile Neoplasms |
Details
|
Bintrafusp alfa |
M-7824; GSK-4045154; MSB-0011359C |
Phase 3 Clinical |
Merck Serono |
Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
MAX-10181 |
MAX-10181; MAX-1 |
Phase 1 Clinical |
Guangzhou Maxinovel Pharmaceiticals Co Ltd |
Solid tumours |
Details
|
PM-8001 |
6MW3111; PM-8001 |
Phase 2 Clinical |
Pumis Biotechnology (Zhuhai) Co Ltd |
Solid tumours; Lung Neoplasms |
Details
|
ABL-503 |
ABL-503 |
|
Abl Bio Inc |
|
Details
|
Lodapolimab |
LY-3300054 |
Phase 1 Clinical |
Eli Lilly And Company |
Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
TQB-2450 |
APL-502; CBT-502; TQ-B2450 |
Phase 3 Clinical |
Cbt |
Cholangiocarcinoma; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lymphoma; Fallopian Tube Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Lymphoma, B-Cell; Liver Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms |
Details
|
Recombinant anti-PD-L1 human monoclonal antibody (Hisun Pharm) |
HS-636 |
Phase 1 Clinical |
Zhejiang Hisun Pharmaceutical Co Ltd |
Neoplasms |
Details
|
SHR-1316 |
SHR-1316 |
Phase 3 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) |
LP-002 |
Phase 2 Clinical |
Taizhou Houde Aoke Technology Co Ltd |
Solid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma |
Details
|
KN-046 |
KN046; KN-046 |
Phase 3 Clinical |
Suzhou Alphamab Co Ltd |
Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Thymus Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms |
Details
|
GR-1405 |
GR-1405 |
Phase 2 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd |
Head and Neck Neoplasms; Solid tumours; Nasopharyngeal Carcinoma; Lymphoma |
Details
|
SHR-1701 |
SHR-1701 |
Phase 2 Clinical |
Jiangsu Hengrui Medicine Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
Recombinant human anti-PD-L1 monoclonal antibody (Zhaoke Oncology) |
ZKAB001; STI-A1014; STIA-1014 |
Phase 3 Clinical |
Zhaoke (Guangzhou) Oncology Pharmaceutical Ltd |
Biliary Tract Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Osteosarcoma; Bile Duct Neoplasms; Uterine Cervical Neoplasms |
Details
|